The frequency of ESBL producing bacterial infections and related antimicrobial susceptibility in ICU patients: A five-year longitudinal study ESBL producing bacterial infections in ICU

Creative Commons License

Onuk S., Coruh A. E., Kilic A. U., EREN E., GÜNDOĞAN K.

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, cilt.14, 2023 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14
  • Basım Tarihi: 2023
  • Doi Numarası: 10.4328/acam.21589
  • Dergi Adı: ANNALS OF CLINICAL AND ANALYTICAL MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Anahtar Kelimeler: Intensive Care Unit, ESBL-Producing Bacteria, Nosocomial Infection, Antibiotic Resistance-Susceptibility
  • Erciyes Üniversitesi Adresli: Evet

Özet

Aim: This study aimed to evaluate the incidence of nosocomial infections caused by extended-spectrum beta-lactamase (ESBL) producing bacteria and related antimicrobial susceptibility in critically ill patients over a 5-year period. Material and Methods: The retrospective study was carried out in critically ill patients infected with ESBL-producing pathogens during intensive care unit (ICU) stay. Participants' medical data between 2014 and 2018 were included. ESBL-positive isolates from clinical specimens were evaluated by species and antibiotic susceptibility. Results: Ninety of 2456 critically ill patients had ESBL-positive bacterial infections. The mean age of the study sample was 58.7 +/- 19.1 years and 53.3% were males. ESBL-producing E. coli was noted in 60 (66.7%) patients, K. pneumoniae in 27 (30.0%) patients and K. oxytoca in 3 (3.3%) patients. Colistin (100%), meropenem (94.9%), imipenem (94.0%), and amikacin (90.0%) were active against >= 90% of ESBL-producing pathogens, while ertapenem (89.4%), fosfomycin (87.5%), tigecycline (80.0%) were active against >= 80% of pathogens in ICU. Susceptibility of ESBL producers was remarkably low against levofloxacin (30.8%) and ciprofloxacin (36.7%). The mortality rate of the sample was 25.5%. Discussion: Our findings revealed that ESBL-producing E. coli was highly responsible for ESBL-positive bacterial infections in ICU. The continued efficacy of colistin, carbapenems and amikacin against ESBL-producing E. coli and K. pneumoniae was exhibited.